EDAP TMS SA - Q3 2025 Financial Summary
Business Context and Reporting Period
This Form 6-K filing reports the unaudited consolidated financial results for EDAP TMS SA for the third quarter and nine months ended September 30, 2025. EDAP is a global leader in robotic energy-based therapies, primarily focused on its Focal One Robotic HIFU platform for early-stage prostate cancer treatment. The company is strategically shifting focus from non-core businesses (ESWL and Distribution) to the high-growth HIFU segment.
Key Financial Metrics
| Metric | Q3 2025 (€) | Q3 2024 (€) | YTD 2025 (€) | YTD 2024 (€) |
|---|---|---|---|---|
| Total Revenue | 13.9M | 13.1M | 43.5M | 43.8M |
| HIFU Revenue | 6.7M | 4.5M | 21.3M | 15.1M |
| Non-Core Revenue | 7.2M | 8.6M | 22.2M | 28.7M |
| Gross Profit | 6.0M | 5.2M | 18.5M | 17.5M |
| Gross Margin | 43% | 39% | 42.5% | 39.9% |
| Operating Loss | (4.9M) | (5.8M) | (16.7M) | (16.8M) |
| Net Loss | (5.0M) | (6.4M) | (17.7M) | (17.1M) |
| Cash & Equivalents (Sep 30) | 10.6M | N/A | 10.6M | N/A |
Liquidity & Debt: As of September 30, 2025, cash and cash equivalents stood at €10.6 million. On October 20, 2025, the company finalized a €36 million credit facility with the European Investment Bank (EIB), with the first tranche of €11 million deposited shortly after.
Material Changes vs. Prior Period
- HIFU Growth: HIFU revenue surged 49% year-over-year in Q3 2025, driven by a 167% increase in Focal One system placements (6 systems sold vs. 3 in Q3 2024) and a 15% increase in U.S. procedure volumes.
- Non-Core Decline: Revenue from non-core businesses (ESWL and Distribution) declined 16% in Q3 and 23% year-to-date, consistent with the strategic decision to divest focus from these segments.
- Margin Expansion: Gross profit margin improved to 43% in Q3 (from 39% in Q3 2024) due to a favorable product mix shift toward higher-margin HIFU systems and better absorption of fixed costs.
- Loss Reduction: Net loss narrowed to €5.0 million in Q3 2025 compared to €6.4 million in the prior year period, despite stable operating expenses.
Guidance, Outlook, and Risks
2025 Guidance: The company is reiterating its full-year 2025 guidance:
- Core HIFU Revenue: Expected to grow 26% to 34% year-over-year.
- Non-Core Revenue: Expected to decline 25% to 30% year-over-year.
Management Commentary: CEO Ryan Rhodes highlighted a "paradigm shift" in prostate cancer management, with increasing demand for non-invasive focal therapy. The company noted broader hospital adoption and expanded insurance coverage in the U.S.
Risks & Contingencies: Forward-looking statements are subject to risks including clinical status and market acceptance of HIFU devices, global inflation, geopolitical instability, and potential public health crises. The filing notes that actual results may differ materially from projections.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of operations given the €10.6M cash balance and negative operating cash flow of €12.5M for the nine months ended September 30, 2025.
- Debt Covenants: Review the specific terms and covenants of the new €36M EIB credit facility to ensure compliance.
- System Placement Quality: Confirm the conversion rate of the 167% increase in system placements into recurring disposable revenue.
- Non-Core Divestiture: Monitor the timeline and financial impact of the continued decline in ESWL and Distribution revenues.
- U.S. Reimbursement: Validate the extent of expanded insurance provider coverage cited as a driver for U.S. procedure growth.